Spero Therapeutics, Inc.SPROEarnings & Financial Report
Nasdaq
SPRO Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-7.9M
Net Profit
$-7.4M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.13
Spero Therapeutics, Inc. Q3 2025 Financial Summary
Spero Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-7.4M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-7.4M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Spero Therapeutics, Inc. Annual Revenue by Year
Spero Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $371.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $371.0K |
| 2023 | $933.0K |
| 2022 | $48.6M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $-24.0M | $140000 | $114000 | $65000 | $52000 | $12000 | $0 | $0 |
| YoY Growth | -151.7% | -81.1% | -85.5% | -99.7% | 100.2% | -91.4% | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $182.4M | $167.7M | $149.9M | $135.2M | $110.5M | $77.7M | $62.1M | $54.2M |
| Liabilities | $75.5M | $71.5M | $69.4M | $69.7M | $64.4M | $43.9M | $29.3M | $27.7M |
| Equity | $106.9M | $96.2M | $80.5M | $65.5M | $46.1M | $33.8M | $32.8M | $26.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-17.5M | $5.9M | $-18.7M | $12.8M | $-23.4M | $-4.0M | $-17.7M | $17.4M |